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ABSTRACT 
 
Studies on enzyme inhibition remain an important area of pharmaceutical research since these 
studies have led to the discoveries of drugs useful in a variety of physiological conditions. The 
enzyme inhibitors can interact with enzymes and block their activity towards natural substrates. 
Urease inhibitors have recently attracted much attention as potential new anti-ulcer drugs. A 
series of novel substituted pyrazoles 8(a-j)    has been synthesized  by diazotization of fluoro 
chloro aniline (1) and the reaction of the corresponding diazonium salt solution (2) with ethyl 
cyanoacetate (3) to give the intermediate, ethyl 2-((3-chloro-4-fluorophenyl) diazenyl-2-
cyanoacetate (4). The intermediate is then cyclised with chloroacetonitrile (5) using triethyl 
amine as the base to give the final compound, ethyl 4-amino-1-(3-chloro-4-flurophenyl)-5-
cyano-1H-pyrazole-3-carboxylate (6). Nucleophilic substitution group is removed from the final 
compound and 8(a-j) derivatives have been synthesized. All the synthesized compounds were 
characterized by physical data (M.P. & TLC) and spectral Data (IR & 1H NMR). The 
synthesized compounds were evaluated for urease-inhibition activity. Molecular docking studies 
were carried out for these compounds with the enzyme urease. From the observations it has been 
noticed that some of the compounds possesses remarkable urease-inhibitory effect. 
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INTRODUCTION 
 
Urease is directly involved in the formation of infection stones and contributes to the 
pathogenesis of urolithiasis, pyelonephritis, ammonia and hepatic encephalopathy, hepatic coma 
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and urinary catheter encrustation.urease is known to be the major cause of pathologies induced 
by helicobacter pylori (HP) which allow HP to survive at low pH of the stomach and therefore 
play an important role in pathogenesis of gastric and peptic ulcer which in some cases may 
progress of cancer [1-3]. 
 
Literature survey reveals that the Urease inhibition having some medically importance against to 
treat ulcer [4-8]. In recent year heterocyclic compounds analogues and derivatives have attracted 
strong interest due to their useful biological and pharmacological properties. 
 
Pyrazole and its derivatives are known to be biologically active compounds. And Substituted 
pyrazoles have shown wide range of biological activities like antioxidant[9,16] 
antibacterial[9,11,13,16],antifungal[14,23],analgesic[15],lipidperoxidation[15],antiinflammatory[9,12,15], 
Anti atherosclerosis [17], antidepresent [18], antitumour activities [21], etc .In view of these and our 
continuing interest in the synthesis of biologically active compounds. Hence we have chosen the 
title topic for our research. 
 
The most recent phase in the new drug discovery process is utilizing the knowledge of the three 
dimensional structures of target macromolecules or of related proteins. The same strategy is used 
in present study to know the binding of the newly synthesized pyrazoles to selected protein sites. 
It was theoretically predicted that how inhibitors bind to the molecular targets, specific 
interactions that are important in the molecular recognition 
 
MATERIALS AND METHODS 
 
Standard chemicals are purchased from chemfort (India) Pvt.ltd. And sd fine Chemical Pvt ltd. 
Melting points were determined in open capillaries and are uncorrected.IR spectra were recorded 
Shimadzu FTIR5400. Infrared spectrophotometer using KBr.1HNMR spectra were recorded on 
Perkin-Elmer, 90 MHz spectrophotometer. Using TMS as standard (chemical shift in δ ppm) 
 
General procedure for Synthesis of 1-chloro-2-(3-chloro-4-fluorophenyl) diazene (2): 
A mixture of (0.18 mol) of fluoro chloro aniline with 46ml of conc. HCl and 75 ml of water 
taken in a glass mortar. Transferred this suspension to a 500 ml RBF and stirred well. Cooled the 
contents of the flask in an ice bath to 0-5°C and, added a solution of 13.0g (0.19 mol) of sodium 
nitrite in 175 ml of water from a dropping funnel during about 20 minutes. Kept the diazonium 
salt solution below 5°C and, filtered.  
 
Synthesis of ethyl 2-((3-chloro-4-flurophenyl) diazenyl)-2-cyanoacetate (4): 
Sodium acetate (20 mmol) was added to ethyl cyanoacetate (17.3 mmol), which was dissolved in 
ethanol (120 ml), cooled below 5°C, and the previously prepared diazonium salt was added with 
vigorous mechanical stirring. Stirring was continued for 2 hr at room temperature. The 
precipitate was filtered off, washed twice with water and finally dried at 50°C the synthesized 
compounds were characterized by elemental and spectral analysis. 
 
FT-IR cm-1spectra of Comp No. 4 
Data: 2222(CN); 2978.19(CH), 1465 (CH2) 1718 (C=O);   761(Ar- Cl); 1263(C-F). 
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1H NMR spectra of Comp No. 4 Data: 7.502-7.474 (d, 1H, J=5.45, CH at I), 7.2097.131(d, 2H, 
J=6.55, CH at II and III). 1.634(s, 1H, CH at IV).4.431, (q, 2H, CH2 at V).1.370 (t, 3H, CH3 at 
VI) 
 
Synthesis of substituted ethyl 4-amino-1-(3-chloro-4-fluorophenyl)-5-cyano-1H-pyrazole-3-
carboxylate(6): 
To the intermediate (4) 1mmol chloroacetonitrile (1ml) was added and then NEt3 (5 mmol) drop 
wise with external cooling. Mixture was heated at 80-90°C during 1-4hours. After cooling, water 
was added (10-15ml) and brown oil separated. Water was decanted and the oil dissolved in ethyl 
acetate, dried and evaporated to produce brown oil again.  
 
The oil was scratched with 10 percent solution of ethyl acetate in ether, solidified and the 
product was filtered and washed with ether, which yielded a brown solid. 
 
FT-IR cm-1 spectra of Comp No. 6 Data: 3390(NH2); 2216(CN) 1691 (C=O); 827(Ar- Cl); 
1263(C-F); 1454(CH2)1527(Ar C=C); 2982(CH). 
 
1H NMR spectra of Comp No. 6 Data: 7.822-7.778 (m, 1H, CH at I). 7.359-7.317 (d, 1H, CH 
at II). 7.644-7.567 (m, 1H, CH at III). 4.527-4.414 (m, 2H, NH2 at IV). 1.589 (m, 2H, CH2 at V).  
1.475-1.404(t, 3H, CH2 at VI) 
 
Synthesis of substituted ethyl 4-amino-1-(3-substituted-4-fluorophenyl)-5-cyano-1H-
pyrazole-3-carboxylate (8a-j): 
To the above ethyl 4-amino-1-(3-chloro-4-fluorophenyl)-5-cyano-1H-pyrazole-3-carboxylate 
derivative (1mol), different types anilines( 3-Nitro aniline, 4-chloro aniline) or phenol (o- cresol, 
p- cresol )  (1mol), 1,4-dioxane 10 ml and 2-3 drops of triethylamine was taken in a 100 ml RBF 
fitted with a reflux condenser. Refluxed the reaction mixture 12-14 hr and monitored by TLC, 
then transferred to ice cold water and filtered the solution to get the desired products. 
 
FT-IR cm-1 spectra of Comp No. 8a 
 Data: 3232(NH2); 2216(CN); 1703 (C=O); 1271(C-F); 1444(CH2); 1558(Ar C=C); 2985( CH); 
1330(C-O), 1228(C-C).   
FT-IR spectra of Comp No. 8i  Data: 3367(NH2); 2360(CN); 1718 (C=O); 1261(C-F); 
1438(CH2); 1535(Ar C=C); 2935(CH); 1103(C-O), 1230(C-C). 
 
Biological Evaluation 
Urease inhibition activity  
Enzyme Source.  Fresh Watermelon was purchased from main vegetable markets in Bangalore 
in February 2011. And authenticated by Botanist, 
 
Preparation of Extract 
5gm of Watermelon seeds are soaked in water for overnight. Homogenized the soaked seeds 
with 50ml of 100mM phosphate buffer pH 6.8 and allowed to stand for 30mins with occasional 
agitation. The suspension was then centrifuged at 3000rpm for 15min.Decant the supernatant 
into a clean glass beaker, which contains urease and stored in cold condition. 
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Standard curve for ammonia estimation 
0.2-1.0 ml different aliquots of standard ammonium sulphate solution and water taken  in to 
different test tubes followed by 1.0ml of Nessler’s reagent to all the test tubes. Read the 
absorbance at 490nm against blank. (Table 1) 
 
Enzyme assay  
In Two different test tubes blank and test. Taken 1.0 ml of 100Mm of phosphate buffer, 1.0ml of 
urea solution and. 0. 2 ml Enzyme extract is added to the test only and incubate at37°c in a water 
bath exactly for 30minutes, with constant gentle shaking.  7N Sulphuric acid is added to each test 
tube to arrest the reaction. 0.2ml of enzyme extract is added to the blank. 
 
After completion of enzymatic reaction both in blank and test, centrifuge the contents at room 
temperature for 15mins at 3500rpm. 0.2 ml of the supernatant is used for ammonium  
Estimation. (Table 2) 
 
Molecular Docking Studies: 
The newly synthesized compounds were subjected for molecular docking by calculating the 
minimum energy by inhibiting the target protein involved in the inflammation pathway. The 
ligands were drawn in ChemDraw Ultra 6.0 assigned with proper 2D orientation (Chem Office 
package) and the structure of each ligand was analyzed by using Chem-3D Ultra 6.0 
(ChemOffice package) and was checked for the connection error in bond order. ADMET 
property was achieved through Pre ADMET server- a web-based application for predicting 
ADMET data and building drug-like library using in silico method. Energy of the molecules was 
minimized using Dundee PRODRG2 Server. Then the file was opened in SPDB viewer and C-
terminal Oxygen was added using fit module property. CASTp (Computed Atlas of Surface 
Topography of proteins) server was used to identify the active pockets on target protein 
molecules. Autodock V3.0 was used to perform Molecular Docking. (Table 4) 
 
Table 1. Standard curve for ammonia estimation 
 
Sl.No Vol of ammonium sulphate 
sol (ml) 
Conc. Of 
ammonia(µg) 
Vol of distill 
water (ml) 
Nessler’s 
reagent(ml) 
0.D at 
480nm 
1 0.0 0.0 12.0 1.0 0.00 
2 0.2 2.0 11.8 1.0 0.02 
3 0.4 4.0 11.6 1.0 0.04 
4 0.6 6.0 11.4 1.0 0.06 
5 0.8 8.0 11.2 1.0 0.08 
6 1.0 10.0 11.0 1.0 0.10 
 
Table 2. Enzyme Assay 
 
 Po4 Buffer Urea H2So4 Enz Nessler’s Water O.D 
Activity 
(µmol/ml/min) 
Ec(Control) -- 1ml 0.5 ml 0.2 ml 1.0ml 10.3ml 0.0 ---- 
Et(Test) 0.2 ml 1ml 0.5 ml 
 
1.0ml 10.3ml 0.55 0.12 
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Table 3.Inhibition studies 
 
Compound 
No 
Vol of enzyme + 
inhibitor 
Vol of distill 
water 
Nessler’s reagent 
(ml) 
O.D at 480 
nm 
Activity 
(µmol/ml/min) 
4 0.1+0.1 11.8 1.0 0.09 0.0247 
6 0.1+0.1 11.8 1.0 0.33 0.06594 
8b 0.1+0.1 11.8 1.0 0.41 0.08242 
8c 0.1+0.1 11.8 1.0 0.68 0.1569 
8d 0.1+0.1 11.8 1.0 0.64 0.1348 
 
Table 4: Molecular docking details of all the compounds with Urease enzyme 
 
Molecule Binding 
energy 
Docking 
energy 
Inhibitory 
constant 
Intermol 
energy 
H-
bonds Bonding 
4 -3.25 -1.91 0.0 -4.81 2 UR:A:MET637:HN::4:DRG1:OAO UR:A:GLY638:HN::4:DRG1:O 
6 -6.03 -6.49 3.82e-005 -6.34 2 UR:A:MET637:HN::6:DRG1:NAO UR:A:GLY638:HN::6:DRG1:NAO 
8a 16.01 15.07 -- 14.45 -- ------------------------------ 
8b 15.04 14.42 -- 13.48 1 UR:A:ARG639:HH11::8b:DRG1:OAX 
8c 21.2 20.51 -- 19.33 -- ------------------------------ 
8d 34.61 34.47 -- 32.43 -- ------------------------------ 
8e 27.03 28.17 -- 24.85 -- ------------------------------ 
8f 26.07 30.02 -- 23.89 -- ------------------------------ 
8g 45.19 44.85 -- 43.32 -- ------------------------------ 
8h 48.20 40.16 -- 42.09 -- ------------------------------ 
8i 50.03 51.3 -- 46.70 -- ------------------------------ 
8j 52.34 55.67 -- 58.71 -- ------------------------------ 
 
 
 
 
Fig 1: Docking postures of the compounds 4, 6 and 8b with Urease showing hydrogen bonds. 
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RESULT AND DISCUSSION 
 
Urease was extracted from watermelon seeds and screened its inhibition studies using substituted 
fluoro pyrazole derivatives. We found that. The synthesized compounds No 4, 6, and 8b have 
very good inhibition activity against urease. 
 
The docking postures are shown in fig 1. Binding energy and hydrogen bonds formed are 
tabulated in the table. The theoretical outcome highlight that the minimum binding energy of the 
molecules with the targeted protein may make these newly synthesized pyrazoles as good 
inhibitors for inflammation. However, these promising results are reliable and further can be 
subjected for preclinical studies to arrive at the conclusion on these molecules for their clinical 
use. 
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